Lately, the pivotal role of the PI3K/Akt axis in breast carcinogenesis has been characterized, prompting the development of recent therapeutic strategies that could inhibit this pathway aiming at both limiting tumor proliferation and/or survival as well as reviving tumor functional immunosurveillance. The gene discussed is PIK3CB; the disease is neoplasm.